Evidence map›Paper›PMID 41693373›Full record

Trial reportClinical pharmacology in drug development2026

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of Firsekibart in Chinese Healthy Participants.

Xiaolan Yong, Xiaolin Du, Xiao Li, Yushi Chen, Xiaoyan Zhu, Tianhong Luo, Qian Xu

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaolan YongPhase I Clinical Trial Center, Chengdu Xinhua Hospital, Chengdu, China.
Xiaolin DuPhase I Clinical Trial Center, Chengdu Xinhua Hospital, Chengdu, China.
Xiao LiPhase I Clinical Trial Center, Chengdu Xinhua Hospital, Chengdu, China.
Yushi ChenPhase I Clinical Trial Center, Chengdu Xinhua Hospital, Chengdu, China.
Xiaoyan ZhuChangchun GeneScience Pharmaceutical Co., Ltd, Shanghai, China.
Tianhong LuoChangchun GeneScience Pharmaceutical Co., Ltd, Shanghai, China.
Qian XuChangchun GeneScience Pharmaceutical Co., Ltd, Shanghai, China.

Funding

Changchun GeneScience Pharmaceutical Co., Ltd.
6 · The paper itself

Abstract

Firsekibart is an anti-IL-1β monoclonal antibody for treating acute gout flares in adults. This randomized, double-blind, placebo-controlled study assessed the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple ascending doses of firsekibart in healthy Chinese adults. Participants were assigned to one of the two firsekibart cohorts (120 or 200 mg) every 4 weeks for three doses and randomized in a 5:1 ratio to receive firsekibart or placebo. Twenty-four participants completed the study. After a single dose, the median T

Indexed as

Antibodies, MonoclonalInterleukin-1betaAdultArea Under CurveChinaDose-Response Relationship, DrugDouble-Blind MethodFemaleHealthy VolunteersHumansMaleMiddle AgedYoung AdultAntibodies, MonoclonalIL1B protein, humanInterleukin-1betafirsekibartmultiple ascending dosepharmacokineticsphase 1 studysafety

Identifiers

PMID41693373
PMCPMC12907776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.